355 related articles for article (PubMed ID: 24777808)
1. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
2. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Song Z; Yu X; Cai J; Shao L; Lin B; He C; Zhang B; Zhang Y
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):138-43. PubMed ID: 23514942
[TBL] [Abstract][Full Text] [Related]
4. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Shao L; Zhang B; He C; Lin B; Song Z; Lou G; Yu X; Zhang Y
Chin Med J (Engl); 2014; 127(2):266-71. PubMed ID: 24438614
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
7. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
9. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Biaoxue R; Hua L; Wenlong G; Shuanying Y
Oncotarget; 2016 Dec; 7(52):86902-86913. PubMed ID: 27893423
[TBL] [Abstract][Full Text] [Related]
12. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Yang G; Yao Y; Zhou J; Zhao Q
Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
14. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Tan F; Shi Y; Wang Y; Ding L; Yuan X; Sun Y
Future Oncol; 2015; 11(3):385-97. PubMed ID: 25675121
[TBL] [Abstract][Full Text] [Related]
15. [Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Li X; Yang XJ; Sun YF; Qin N; Lü JL; Wu YH; Zhang H; Zhang Q; Zhang SC
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):627-31. PubMed ID: 23159001
[TBL] [Abstract][Full Text] [Related]
16. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
[TBL] [Abstract][Full Text] [Related]
17. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
[TBL] [Abstract][Full Text] [Related]
18. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
20. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Ni J; Liu DY; Hu B; Li C; Jiang J; Wang HP; Zhang L
Cancer; 2015 Sep; 121 Suppl 17():3146-56. PubMed ID: 26331821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
